These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8744563)

  • 1. Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gp120-iscom preparations. A comparison with other adjuvant systems.
    Sjölander S; Hansen JE; Lövgren-Bengtsson K; Akerblom L; Morein B
    Vaccine; 1996 Mar; 14(4):344-52. PubMed ID: 8744563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
    Bolmstedt A; Sjölander S; Hansen JE; Akerblom L; Hemming A; Hu SL; Morein B; Olofsson S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):213-20. PubMed ID: 8673525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120).
    Pyle SW; Morein B; Bess JW; Akerblom L; Nara PL; Nigida SM; Lerche NW; Robey WG; Fischinger PJ; Arthur LO
    Vaccine; 1989 Oct; 7(5):465-73. PubMed ID: 2554608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
    J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
    Akerblom L; Nara P; Dunlop N; Putney S; Morein B
    Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporation of soluble antigens into ISCOMs: HIV gp120 ISCOMs induce virus neutralizing antibodies.
    Browning M; Reid G; Osborne R; Jarrett O
    Vaccine; 1992; 10(9):585-90. PubMed ID: 1380196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.
    Verschoor EJ; Mooij P; Oostermeijer H; van der Kolk M; ten Haaft P; Verstrepen B; Sun Y; Morein B; Akerblom L; Fuller DH; Barnett SW; Heeney JL
    J Virol; 1999 Apr; 73(4):3292-300. PubMed ID: 10074183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of delivery system enhances MHC nonrestricted immunogenicity of V3 loop region of HIV-1 gp120.
    Ahluwalia A; Gokulan K; Nath I; Rao DN
    Microbiol Immunol; 1997; 41(10):779-84. PubMed ID: 9403501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of nucleic acid and protein immunization for induction of antibodies specific for HIV-1 gp120.
    Peet NM; McKeating JA; Ramos B; Klonisch T; De Souza JB; Delves PJ; Lund T
    Clin Exp Immunol; 1997 Aug; 109(2):226-32. PubMed ID: 9276516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies.
    Kim YB; Han DP; Cao C; Cho MW
    Virology; 2003 Jan; 305(1):124-37. PubMed ID: 12504547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.
    Ahmed FK; Clark BE; Burton DR; Pantophlet R
    Vaccine; 2012 Jan; 30(5):922-30. PubMed ID: 22142583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of iscoms and their adjuvant moiety (matrix) on the initial proliferation and IL-2 responses: comparison of spleen cells from mice inoculated with iscoms and/or matrix.
    Fossum C; Bergström M; Lövgren K; Watson DL; Morein B
    Cell Immunol; 1990 Sep; 129(2):414-25. PubMed ID: 2383899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.
    Liao HX; Etemad-Moghadam B; Montefiori DC; Sun Y; Sodroski J; Scearce RM; Doms RW; Thomasch JR; Robinson S; Letvin NL; Haynes BF
    J Virol; 2000 Jan; 74(1):254-63. PubMed ID: 10590113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs.
    Powell MF; Eastman DJ; Lim A; Lucas C; Peterson M; Vennari J; Weissburg RP; Wrin T; Kensil CR; Newman MJ
    AIDS Res Hum Retroviruses; 1995 Feb; 11(2):203-9. PubMed ID: 7742035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of immunostimulating complexes (ISCOMS) of HIV-1.
    Höglund S; Akerblom L; Ozel M; Villacres M; Eriksson M; Gelderblom HR; Arthur L; Morein B
    Viral Immunol; 1990; 3(3):195-206. PubMed ID: 2257052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix.
    Rönnberg B; Fekadu M; Morein B
    Vaccine; 1995 Oct; 13(14):1375-82. PubMed ID: 8585296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.
    González AM; Nguyen TV; Azevedo MS; Jeong K; Agarib F; Iosef C; Chang K; Lovgren-Bengtsson K; Morein B; Saif LJ
    Clin Exp Immunol; 2004 Mar; 135(3):361-72. PubMed ID: 15008967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.